Pharsight

Lnhc patents expiration

1. Sitavig patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791127 LNHC Mucosal bioadhesive slow release carrier for delivering active principles
Mar, 2027

(2 years from now)

US8747896 LNHC Mucosal bioadhesive slow release carrier for delivering active principles
Jun, 2027

(3 years from now)

US8592434 LNHC Mucoadhesive buccal tablets for the treatment of orofacial herpes
Jun, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 12, 2016

Drugs and Companies using ACYCLOVIR ingredient

Market Authorisation Date: 12 April, 2013

Treatment: Treatment of herpes labialis

Dosage: TABLET;BUCCAL

More Information on Dosage

SITAVIG family patents

Family Patents

2. Zelsuvmi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8956658 LNHC Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
May, 2026

(2 years from now)

US8282967 LNHC Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
May, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9737561 LNHC Topical gels and methods of using the same
Aug, 2030

(6 years from now)

US10376538 LNHC Topical gels and methods of using the same
Aug, 2030

(6 years from now)

US9526738 LNHC Topical gels and methods of using the same
Sep, 2031

(7 years from now)

US10265334 LNHC Anhydrous compositions
Jul, 2032

(8 years from now)

US9289442 LNHC Topical compositions
Jul, 2032

(8 years from now)

US9855211 LNHC Topical compositions and methods of using the same
Feb, 2034

(9 years from now)

US11285098 LNHC Topical compositions and methods of using the same
Feb, 2034

(9 years from now)

US10258564 LNHC Topical compositions and methods of using the same
Nov, 2034

(10 years from now)

US11040006 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(11 years from now)

US10322081 LNHC Topical antiviral compositions and methods of using the same
Jul, 2035

(11 years from now)

US11723858 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(11 years from now)

US10736839 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 05, 2029

Drugs and Companies using BERDAZIMER SODIUM ingredient

NCE-1 date: 06 January, 2028

Market Authorisation Date: 05 January, 2024

Treatment: Method of treating skin ailment with nitric oxide releasing macromolecules and hydrophilic gel; Method of application of topical pharmaceutical composition to treat dermatological condition; Method of...

Dosage: GEL;TOPICAL

More Information on Dosage

ZELSUVMI family patents

Family Patents